The design and synthesis of lincomycin derivatives modified at the C-6 and C-7 positions are described. A substituent at the C-7 position is a 5-aryl-1,3,4-thiadiazol-2-yl-thio group that generates antibacterial activities against macrolide-resistant Streptococcus pneumoniae and Streptococcus pyogenes carrying an erm gene. An additional modification at the C-6 position was explored in application of information regarding pirlimycin and other related compounds. These dual modifications were accomplished by using methyl α-thiolincosaminide as a starting material. As a result of these dual modifications, the antibacterial activities were improved compared with those of compounds with a single modification at the C-7 position. The antibacterial activities of selected compounds in this report against macrolide-resistant S. pneumoniae and S. pyogenes with an erm gene were superior to those of telithromycin.

中文翻译：

---

新型林可霉素衍生物的合成和抗菌活性。IV。N-6取代基的优化。

描述了在C-6和C-7位置修饰的林可霉素衍生物的设计和合成。C-7位的取代基是5-芳基-1,3,4-噻二唑-2-基-硫基，该基团对带有erm基因的耐大环内酯性肺炎链球菌和化脓性链球菌产生抗菌活性。在应用有关Pirlimycin和其他相关化合物的信息时，还探索了C-6位的其他修饰。这些双重修饰是通过使用甲基α-硫代林糖胺作为起始原料来完成的。这些双重修饰的结果是，与在C-7位置具有单一修饰的化合物相比，抗菌活性得到了提高。本报告中所选化合物对大环内酯类耐药肺炎链球菌和肺炎链球菌的抗菌活性。